Higher diet quality can combat cardiovascular disease: McMaster-led study

The study tracked 26,539 people from 33 countries in Asia, Europe, Australia North and South America with both CAD and PAD. Of the patients tracked, 24,119 had CAD and 7,163 had PAD, with some having both. Participants’ average age was 68 years old and 78 per cent were men.
Over the 30 months that participants were monitored, a total of 1,391 adverse events occurred, of which 1,262 were CVD-related and 140 were PAD-related, with some people having both.
Researchers found the incidence of CVD and PAD events was highest in patients with a poor diet, measured by the Alternate Healthy Eating Index (AHEI) metric, with zero being the worst diet score and 70 being the best.

Randomized Clinical Trial Finds No Mortality Risk or Benefit Associated with Drug-Coated Devices in the Treatment of Peripheral Artery Disease

A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used.